Suppr超能文献

氯喹和羟氯喹治疗 COVID-19 的疗效。

Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.

机构信息

Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

出版信息

Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4539-4547. doi: 10.26355/eurrev_202004_21038.

Abstract

OBJECTIVE

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called COVID-19, has caused a pandemic which has swiftly involved the entire world and raised great public health concerns. The scientific community is actively exploring treatments that would potentially be effective in combating COVID-19. Hydroxychloroquine has been demonstrated to limit the replication of SARS-CoV-2 virus in vitro. In malarial pandemic countries, chloroquine is widely used to treat malaria. In malarial non-pandemic nations, chloroquine is not widely used. Chloroquine and hydroxychloroquine share similar chemical structures and mechanisms of action. The aim of this study was to indirectly investigate the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19 by determining the prevalence of COVID-19 in malaria pandemic and non-pandemic nations. We sought evidence to support or refute the hypothesis that these drugs could show efficacy in the treatment of COVID-19.

MATERIALS AND METHODS

We reviewed in vitro studies, in vivo studies, original studies, clinical trials, and consensus reports, that were conducted to evaluate the antiviral activities of chloroquine and hydroxychloroquine. The studies on "COVID-19 and its allied treatment were found from World Health Organization (WHO), ISI-Web of Science, PubMed, EMBASE, Scopus, Google Scholar, and clinical trial registries. The search was based on keywords: antiviral drugs, chloroquine, hydroxychloroquine, COVID-19, COVID-19 treatment modalities, and coronavirus. In addition, we analyzed the prevalence of COVID-19 in malaria pandemic and non-pandemic countries. The review and analyses were performed on March 28, 2020.

RESULTS

For this study, we identified a total of 09 published articles: 03 clinical trials with sample size 150; 03 in vitro studies and 03 expert consensus reports. These studies were all suggestive that chloroquine and hydroxychloroquine can successfully treat COVID-19 infections. We found that COVID-19 infections are highly pandemic in countries where malaria is least pandemic and are least pandemic in nations where malaria is highly pandemic.

CONCLUSIONS

Chloroquine and hydroxychloroquine have antiviral characteristics in vitro. The findings support the hypothesis that these drugs have efficacy in the treatment of COVID-19. People are currently using these drugs for malaria. It is reasonable, given the hypothetical benefit of these two drugs, that they are now being tested in clinical trials to assess their effectiveness to combat this global health crisis.

摘要

目的

新型严重急性呼吸综合征冠状病毒 2(SARS-CoV-2),也称为 COVID-19,已引发大流行,迅速波及全球,引起了公众对健康的极大关注。科学界正在积极探索可能对抗 COVID-19 的有效治疗方法。羟氯喹已被证明可在体外抑制 SARS-CoV-2 病毒的复制。在疟疾大流行国家,氯喹被广泛用于治疗疟疾。在非疟疾大流行国家,氯喹并未广泛使用。氯喹和羟氯喹具有相似的化学结构和作用机制。本研究旨在通过确定疟疾大流行和非大流行国家 COVID-19 的患病率,间接研究氯喹和羟氯喹治疗 COVID-19 的疗效。我们寻找证据来支持或反驳这些药物在治疗 COVID-19 方面可能有效的假设。

材料和方法

我们综述了评估氯喹和羟氯喹抗病毒活性的体外研究、体内研究、原始研究、临床试验和共识报告。我们从世界卫生组织(WHO)、ISI-Web of Science、PubMed、EMBASE、Scopus、Google Scholar 和临床试验注册处查找了“COVID-19 及其联合治疗”的研究。搜索基于以下关键词:抗病毒药物、氯喹、羟氯喹、COVID-19、COVID-19 治疗方法和冠状病毒。此外,我们分析了疟疾大流行和非大流行国家 COVID-19 的患病率。本综述和分析于 2020 年 3 月 28 日进行。

结果

对于本研究,我们共确定了 09 篇已发表的文章:3 项样本量为 150 人的临床试验;3 项体外研究和 3 项专家共识报告。这些研究均表明氯喹和羟氯喹可成功治疗 COVID-19 感染。我们发现,疟疾大流行程度最低的国家 COVID-19 感染高度流行,疟疾大流行程度最高的国家 COVID-19 感染程度最低。

结论

氯喹和羟氯喹在体外具有抗病毒特性。这些发现支持了这些药物在治疗 COVID-19 方面有效的假设。人们目前正在使用这些药物治疗疟疾。考虑到这两种药物的假设益处,目前正在临床试验中测试它们以评估其对抗这一全球健康危机的有效性是合理的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验